MMP-2 and MMP-9 and their tissue inhibitor in preterm human milk

Journal of Pediatric Gastroenterology and Nutrition

Volumn 51, Issue 2, 2010, Pages 210-212

  Lubetzky, Ronit ^a   Mandel, Dror ^b   Mimouni, Francis B ^c   Herman, Lea ^b   Reich, Reuven ^d   Reif, Shimon ^a  

^a Department of Pediatrics ^*  (Australia)

^b LIS MATERNITY HOSPITAL   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

human milk; matrix metalloproteinases; preterm infants; tissue inhibitors

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; BREAST MILK; CLINICAL ARTICLE; COLOSTRUM; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GESTATIONAL AGE; HUMAN; MALE; NEWBORN; OBSERVATIONAL STUDY; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PUERPERIUM; ZYMOGRAPHY;

COLOSTRUM; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MILK, HUMAN; PROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 77955228840     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181d345b8     Document Type: Article

References (17)

1. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154
2. Emonard H, Grimaud JA. Matrix metalloproteinases. A review. Cell Mol Biol 1990;36:131-153
3. Ganea E, Trifan M, Laslo AC, et al. Matrix metalloproteinases: useful and deleterious. Biochem Soc Trans 2007;35:689-691
4. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-283
5. Cheung PY, Sawicki G, Gross S, et al. Differential expression of matrix metalloproteinases and the tissue inhibitor in human milk. Proc West Pharmacol Soc 2001;44:97-98
6. Schulz CG, Sawicki G, Lemke RP, et al. MMP-2 and MMP-9 and their tissue inhibitors in the plasma of preterm and term neonates. Pediatr Res 2004;55:794-801.
7. Schanler RJ, Shulman RJ, Lau C. Feeding strategies for premature infants: beneficial outcomes of feeding fortified human milk versus preterm formula. Pediatrics 1999;103:1150-1157
8. Schanler RJ, Hurst NM, Lau C. The use of human milk and breastfeeding in premature infants. Clin Perinatol 1999;26:379-398
9. Pender SL, Braegger C, Gunther U, et al. Matrix metalloproteinases in necrotising enterocolitis. Pediatr Res 2003;54:160-164
10. Ballin M, Gomez DE, Sinha CC, et al. Ras oncogene mediated activation of a 92 kDa metalloproteinase showing correlation with the malignant phenotype. Biochem Biophys Res Commun 1988;154:832-838
11. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006;11:1696-1701
12. Flannery CR. MMPs and ADAMTSs: functional studies. Front Biosci 2006;11:544-569
13. Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 2006;318:933-938
14. Medina C, Santana A, Paz-Cabrera MC, et al. Increased activity and expression of gelatinases in ischemic colitis. Dig Dis Sci 2006; 51:2393-2399
15. Bister V, Salmela MT, Heikkilä P, et al. Matrilysins-1 and -2 (MMP-7 and -26) and metalloelastase (MMP-12), unlike MMP-19, are upregulated in necrotizing enterocolitis. J Pediatr Gastroenterol Nutr 2005;40:60-66
16. Updegrove K. Necrotizing enterocolitis: the evidence for use of human milk in prevention and treatment. J Hum Lact 2004;20:335-339
17. Schanler RJ. The use of human milk for premature infants. Pediatr Clin North Am 2001;48:207-219